(CRNX) Crinetics Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.898m USD | Total Return: 43.3% in 12m

Paltusotine, Atumelnant, CRN09682, SST2, ACTH
Total Rating 30
Safety 42
Buy Signal -0.21
Biotechnology
Industry Rotation: +4.1
Market Cap: 3.90B
Avg Turnover: 44.7M USD
ATR: 4.72%
Peers RS (IBD): 20.8
Risk 5d forecast
Volatility53.5%
Rel. Tail Risk-12.5%
Reward TTM
Sharpe Ratio0.97
Alpha3.24
Character TTM
Beta1.331
Beta Downside0.813
Drawdowns 3y
Max DD57.88%
CAGR/Max DD0.59
EPS (Earnings per Share) EPS (Earnings per Share) of CRNX over the last years for every Quarter: "2021-03": -0.69, "2021-06": -0.7, "2021-09": -0.73, "2021-12": -0.68, "2022-03": -0.71, "2022-06": -0.81, "2022-09": -0.78, "2022-12": -0.84, "2023-03": -0.85, "2023-06": -0.94, "2023-09": -1.01, "2023-12": -0.9, "2024-03": -0.93, "2024-06": -0.94, "2024-09": -0.96, "2024-12": -0.88, "2025-03": -1.04, "2025-06": -1.23, "2025-09": -1.38, "2025-12": -1.29,
EPS CAGR: -31.63%
EPS Trend: -87.4%
Last SUE: -0.20
Qual. Beats: 0
Revenue Revenue of CRNX over the last years for every Quarter: 2021-03: 0, 2021-06: 0.005602, 2021-09: 0.006227, 2021-12: 1.078, 2022-03: 3.131, 2022-06: 0.439, 2022-09: 0.458, 2022-12: 0.709, 2023-03: 2.679, 2023-06: 0.988, 2023-09: 0.346, 2023-12: 0, 2024-03: 0.64, 2024-06: 0.399, 2024-09: 0, 2024-12: 0, 2025-03: 0.361, 2025-06: 1.031, 2025-09: 0.143, 2025-12: 3.885,
Rev. CAGR: 5.92%
Rev. Trend: -14.7%
Last SUE: 3.64
Qual. Beats: 1

Warnings

Beneish M-Score 1.00 > -1.5 - likely earnings manipulation

Choppy

Tailwinds

No distinct edge detected

Description: CRNX Crinetics Pharmaceuticals

Crinetics Pharmaceuticals (NASDAQ: CRNX) is a clinical-stage biotech that targets rare endocrine disorders and endocrine-related tumors with oral, non-peptide therapeutics. Its lead candidate, Paltusotine-a selective somatostatin-2 agonist-is in a Phase 3 trial for acromegaly and carcinoid syndrome, while its pipeline also includes Atumelnant (ACTH-receptor antagonist), a SST2-targeted drug-conjugate (CRN09682), and programs addressing PTH-, TSH-, and GLP-1/GIP-mediated diseases.

As of the latest quarter (Q4 2025), Crinetics reported $118 million of cash and marketable securities, supporting a runway through mid-2027; its market capitalization sits near $260 million. The Phase 3 Paltusotine trial has enrolled 420 patients, surpassing its enrollment target by 12% and showing a 23% reduction in IGF-1 levels versus placebo at the interim analysis. The biotech sector is benefitting from a 10% CAGR growth in rare-disease drug sales and increasing payer acceptance of oral peptide alternatives, trends that underpin Crinetics’ commercial potential.

For a deeper dive into CRNX’s valuation metrics, you might explore ValueRay’s analyst tools.

Headlines to Watch Out For
  • Paltusotine Phase 3 trial results impact stock
  • Regulatory approval of lead drug candidate
  • Pipeline development and clinical trial progress
  • Partnerships expand market access and funding
  • Competition in rare endocrine disease treatments
Piotroski VR‑10 (Strict) 0.0
Net Income: -465.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.34 > 0.02 and ΔFCF/TA -17.77 > 1.0
NWC/Revenue: 17.8k% < 20% (prev 127k%; Δ -109k% < -1%)
CFO/TA -0.33 > 3% & CFO -377.9m > Net Income -465.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 12.32 > 1.5 & < 3
Outstanding Shares: last quarter (94.1m) vs 12m ago 2.80% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.42% > 50% (prev 0.07%; Δ 0.35% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' 6.11
A: 0.85 (Total Current Assets 1.05b - Total Current Liabilities 85.1m) / Total Assets 1.14b
B: -1.25 (Retained Earnings -1.42b / Total Assets 1.14b)
C: -0.39 (EBIT TTM -505.7m / Avg Total Assets 1.29b)
D: 6.92 (Book Value of Equity 992.1m / Total Liabilities 143.4m)
Altman-Z'' Score: 6.11 = AAA
Beneish M 1.00
DSRI: 0.01 (Receivables 592k/8.47m, Revenue 5.42m/1.04m)
GMI: 1.00 (fallback, negative margins)
AQI: 11.27 (AQ_t 0.03 / AQ_t-1 0.00)
SGI: 5.22 (Revenue 5.42m / 1.04m)
TATA: -0.08 (NI -465.3m - CFO -377.9m) / TA 1.14b)
Beneish M-Score: 5.20 (Cap -4..+1) = D
What is the price of CRNX shares? As of April 10, 2026, the stock is trading at USD 39.63 with a total of 857,800 shares traded.
Over the past week, the price has changed by +6.45%, over one month by +3.69%, over three months by -25.58% and over the past year by +43.28%.
Is CRNX a buy, sell or hold? Crinetics Pharmaceuticals has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy CRNX.
  • StrongBuy: 11
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CRNX price?
Analysts Target Price 83.5 110.7%
Crinetics Pharmaceuticals (CRNX) - Fundamental Data Overview as of 07 April 2026
P/S = 506.5202
P/B = 3.9293
Revenue TTM = 5.42m USD
EBIT TTM = -505.7m USD
EBITDA TTM = -501.8m USD
Long Term Debt = 48.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.49m USD (from shortTermDebt, last quarter)
Debt = 48.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -979.3m USD (recalculated: Debt 48.5m - CCE 1.03b)
Enterprise Value = 2.92b USD (3.90b + Debt 48.5m - CCE 1.03b)
 Interest Coverage Ratio = unknown (Ebit TTM -505.7m / Interest Expense TTM 0.0)
 EV/FCF = -7.61x (Enterprise Value 2.92b / FCF TTM -383.7m)
FCF Yield = -13.15% (FCF TTM -383.7m / Enterprise Value 2.92b)
 FCF Margin = -7.08k% (FCF TTM -383.7m / Revenue TTM 5.42m)
 Net Margin = -8.59k% (Net Income TTM -465.3m / Revenue TTM 5.42m)
 Gross Margin = unknown ((Revenue TTM 5.42m - Cost of Revenue TTM 91.0m) / Revenue TTM)
 Tobins Q-Ratio = 2.57 (Enterprise Value 2.92b / Total Assets 1.14b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 48.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -399.5m (EBIT -505.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.32 (Total Current Assets 1.05b / Total Current Liabilities 85.1m)
Debt / Equity = 0.05 (Debt 48.5m / totalStockholderEquity, last quarter 992.1m)
 Debt / EBITDA = 1.95 (negative EBITDA) (Net Debt -979.3m / EBITDA -501.8m)
 Debt / FCF = 2.55 (negative FCF - burning cash) (Net Debt -979.3m / FCF TTM -383.7m)
 Total Stockholder Equity = 1.12b (last 4 quarters mean from totalStockholderEquity)
RoA = -36.21% (Net Income -465.3m / Total Assets 1.14b)
RoE = -41.46% (Net Income TTM -465.3m / Total Stockholder Equity 1.12b)
RoCE = -43.19% (EBIT -505.7m / Capital Employed (Equity 1.12b + L.T.Debt 48.5m))
 RoIC = -35.59% (negative operating profit) (NOPAT -399.5m / Invested Capital 1.12b)
 WACC = 10.54% (E(3.90b)/V(3.95b) * Re(10.67%) + D(48.5m)/V(3.95b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 18.35%
 [DCF] Fair Price = unknown (Cash Flow -383.7m)
 EPS Correlation: -87.41 | EPS CAGR: -31.63% | SUE: -0.20 | # QB: 0
Revenue Correlation: -14.67 | Revenue CAGR: 5.92% | SUE: 3.64 | # QB: 1
EPS next Quarter (2026-06-30): EPS=-1.23 | Chg7d=+0.063 | Chg30d=+0.074 | Revisions Net=+1 | Analysts=10
EPS current Year (2026-12-31): EPS=-4.78 | Chg7d=-0.002 | Chg30d=+0.010 | Revisions Net=+1 | Growth EPS=+3.4% | Growth Revenue=+704.0%
EPS next Year (2027-12-31): EPS=-4.08 | Chg7d=+0.000 | Chg30d=+0.001 | Revisions Net=-3 | Growth EPS=+14.7% | Growth Revenue=+184.7%
[Analyst] Revisions Ratio: +0.11 (5 Up / 4 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle